CIM
LGND icon

Contravisory Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Contravisory Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$647K Buy
2,048
+28
+1% +$6.6K 0.11% 133
2026
Q1 		$403K Sell
2,020
-16
-0.8% -$3.17K 0.08% 152
2025
Q4 		$385K Sell
2,036
-145
-7% -$27.9K 0.08% 166
2025
Q3 		$386K Sell
2,181
-80
-4% -$11.9K 0.07% 179
2025
Q2 		$257K Buy
+2,261
New +$242K 0.05% 219

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
PWG
Portside Wealth Group Provo, Utah $858M AUM 26.82% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Contravisory Investment Management's LGND Position: Q2 2026 in Review

Contravisory Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 1.4% in Q2 2026, buying an estimated $6.6K and bringing the position to 2,048 shares worth $647K. The position accounts for 0.11% of the portfolio, ranked #133.

Contravisory Investment Management first reported a position in LGND in Q2 2025 and has held it in 5 quarters since. 36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Contravisory Investment Management held 2,048 shares of Ligand Pharmaceuticals worth $647K as of Q2 2026.
  • Contravisory Investment Management bought 28 Ligand Pharmaceuticals shares in Q2 2026, an estimated $6.6K.
  • Ligand Pharmaceuticals made up 0.11% of Contravisory Investment Management's portfolio in Q2 2026, its #133 holding.
  • Contravisory Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.